Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(2):301–305. doi: 10.1038/bjc.1997.49

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.

T Saarto 1, C Blomqvist 1, P Rissanen 1, A Auvinen 1, I Elomaa 1
PMCID: PMC2063283  PMID: 9010042

Abstract

Two hundred and eleven patients with node-positive stage II and III breast cancer were treated with eight cycles of adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt), with and without tamoxifen. All patients had undergone radical surgery, and 148 patients were treated with post-operative radiotherapy in two randomized studies. The impact of haematological toxicity of CAFt on distant disease-free (DDFS) and overall survival (OS) was recorded. Dose intensity of all given cycles (DI), dose intensity of the two initial cycles (DI2) and total dose (TD) were calculated separately for all chemotherapy drugs and were correlated with DDFS and OS. Patients with a lower leucocyte nadir during the chemotherapy had significantly better DDFS and OS (P = 0.01 and 0.04 respectively). Dose intensity of the two first cycles also correlated significantly with DDFS (P = 0.05) in univariate but not in multivariate analysis, while the leucocyte nadir retained its prognostic value. These results indicate that the leucocyte nadir during the adjuvant chemotherapy is a biological marker of chemotherapy efficacy; this presents the possibility of establishing an optimal dose intensity for each patient. The initial dose intensity of adjuvant chemotherapy also seems to be important in assuring the optimal effect of adjuvant chemotherapy.

Full text

PDF
301

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmann D. L., O'Fallon J. R., Scanlon P. W., Payne W. S., Bisel H. F., Edmonson J. H., Frytak S., Hahn R. G., Ingle J. N., Rubin J. A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. Am J Clin Oncol. 1982 Aug;5(4):371–381. doi: 10.1097/00000421-198208000-00005. [DOI] [PubMed] [Google Scholar]
  2. Ang P. T., Buzdar A. U., Smith T. L., Kau S., Hortobagyi G. N. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. J Clin Oncol. 1989 Nov;7(11):1677–1684. doi: 10.1200/JCO.1989.7.11.1677. [DOI] [PubMed] [Google Scholar]
  3. Blomqvist C., Tiusanen K., Elomaa I., Rissanen P., Hietanen T., Heinonen E., Gröhn P. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial. Br J Cancer. 1992 Dec;66(6):1171–1176. doi: 10.1038/bjc.1992.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bonadonna G., Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981 Jan 1;304(1):10–15. doi: 10.1056/NEJM198101013040103. [DOI] [PubMed] [Google Scholar]
  5. Carmo-Pereira J., Costa F. O., Henriques E., Godinho F., Cantinho-Lopes M. G., Sales-Luis A., Rubens R. D. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer. 1987 Oct;56(4):471–473. doi: 10.1038/bjc.1987.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fisher B., Brown A. M., Dimitrov N. V., Poisson R., Redmond C., Margolese R. G., Bowman D., Wolmark N., Wickerham D. L., Kardinal C. G. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990 Sep;8(9):1483–1496. doi: 10.1200/JCO.1990.8.9.1483. [DOI] [PubMed] [Google Scholar]
  7. Fumoleau P., Devaux Y., Vo Van M. L., Kerbrat P., Fargeot P., Schraub S., Mihura J., Namer M., Mercier M. Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group. Drugs. 1993;45 (Suppl 2):38–45. doi: 10.2165/00003495-199300452-00007. [DOI] [PubMed] [Google Scholar]
  8. Geller N. L., Hakes T. B., Petroni G. R., Currie V., Kaufman R. Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy. Cancer. 1990 Oct 15;66(8):1678–1684. doi: 10.1002/1097-0142(19901015)66:8<1678::aid-cncr2820660804>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  9. Glucksberg H., Rivkin S. E., Rasmussen S., Tranum B., Gad-el-Mawla N., Costanzi J., Hoogstraten B., Athens J., Maloney T., McCracken J. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study. Cancer. 1982 Aug 1;50(3):423–434. doi: 10.1002/1097-0142(19820801)50:3<423::aid-cncr2820500307>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  10. Henderson I. C., Gelman R. S., Harris J. R., Canellos G. P. Duration of therapy in adjuvant chemotherapy trials. NCI Monogr. 1986;(1):95–98. [PubMed] [Google Scholar]
  11. Henderson I. C., Hayes D. F., Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol. 1988 Sep;6(9):1501–1515. doi: 10.1200/JCO.1988.6.9.1501. [DOI] [PubMed] [Google Scholar]
  12. Hortobagyi G. N., Bodey G. P., Buzdar A. U., Frye D., Legha S. S., Malik R., Smith T. L., Blumenschein G. R., Yap H. Y., Rodriguez V. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987 Mar;5(3):354–364. doi: 10.1200/JCO.1987.5.3.354. [DOI] [PubMed] [Google Scholar]
  13. Hortobagyi G. N., Buzdar A. U., Bodey G. P., Kau S., Rodriguez V., Legha S. S., Yap H. Y., Blumenschein G. R. High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol. 1987 Feb;5(2):178–184. doi: 10.1200/JCO.1987.5.2.178. [DOI] [PubMed] [Google Scholar]
  14. Howell A., Rubens R. D., Bush H., George W. D., Howat J. M., Crowther D., Sellwood R. A., Hayward J. L., Knight R. K., Bulbrook R. D. A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Recent Results Cancer Res. 1984;96:74–89. doi: 10.1007/978-3-642-82357-2_10. [DOI] [PubMed] [Google Scholar]
  15. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984 Nov;2(11):1281–1288. doi: 10.1200/JCO.1984.2.11.1281. [DOI] [PubMed] [Google Scholar]
  16. Longo D. L., Duffey P. L., DeVita V. T., Jr, Wesley M. N., Hubbard S. M., Young R. C. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol. 1991 Nov;9(11):2042–2051. doi: 10.1200/JCO.1991.9.11.2042. [DOI] [PubMed] [Google Scholar]
  17. Mouridsen H. T., Rose C., Brincker H., Thorpe S. M., Rank F., Fischerman K., Andersen K. W. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. Recent Results Cancer Res. 1984;96:117–128. doi: 10.1007/978-3-642-82357-2_14. [DOI] [PubMed] [Google Scholar]
  18. Pronzato P., Campora E., Amoroso D., Bertelli G., Botto F., Conte P. F., Sertoli M. R., Rosso R. Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol. 1989 Dec;12(6):481–485. doi: 10.1097/00000421-198912000-00004. [DOI] [PubMed] [Google Scholar]
  19. Redmond C., Fisher B., Wieand H. S. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep. 1983 Jun;67(6):519–526. [PubMed] [Google Scholar]
  20. Rodriguez-Kraul R., Hortobagyi G. N., Buzdar A. U., Blumenschein G. R. Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer. 1981 Jul 15;48(2):227–232. doi: 10.1002/1097-0142(19810715)48:2<227::aid-cncr2820480203>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  21. Saarto T., Blomqvist C., Tiusanen K., Gröhn P., Rissanen P., Elomaa I. The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial. Eur J Surg Oncol. 1995 Apr;21(2):146–150. doi: 10.1016/s0748-7983(95)90204-x. [DOI] [PubMed] [Google Scholar]
  22. Samonigg H., Stöger H., Kasparek A. K., Schmid M., Dusleag J., Pfeiffer K., Smola M., Steindorfer P., Lechner P. Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol. 1991;27(6):477–480. doi: 10.1007/BF00685163. [DOI] [PubMed] [Google Scholar]
  23. Senn H. J., Jungi W. F., Amgwerd R., Hochuli E., Ammann J., Engelhart G., Heinz C., Wick A., Enderlin F., Creux G. Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer: 8 year results. Recent Results Cancer Res. 1984;96:90–101. doi: 10.1007/978-3-642-82357-2_11. [DOI] [PubMed] [Google Scholar]
  24. Tancini G., Bonadonna G., Valagussa P., Marchini S., Veronesi U. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol. 1983 Jan;1(1):2–10. doi: 10.1200/JCO.1983.1.1.2. [DOI] [PubMed] [Google Scholar]
  25. Tannock I. F., Boyd N. F., DeBoer G., Erlichman C., Fine S., Larocque G., Mayers C., Perrault D., Sutherland H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1377–1387. doi: 10.1200/JCO.1988.6.9.1377. [DOI] [PubMed] [Google Scholar]
  26. Tormey D., Gelman R., Falkson G. Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial. Am J Clin Oncol. 1983 Feb;6(1):1–18. [PubMed] [Google Scholar]
  27. Walters R. S., Frye D., Buzdar A. U., Holmes F. A., Hortobagyi G. N. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer. 1992 Jan 15;69(2):476–481. doi: 10.1002/1097-0142(19920115)69:2<476::aid-cncr2820690234>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  28. Wood W. C., Budman D. R., Korzun A. H., Cooper M. R., Younger J., Hart R. D., Moore A., Ellerton J. A., Norton L., Ferree C. R. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994 May 5;330(18):1253–1259. doi: 10.1056/NEJM199405053301801. [DOI] [PubMed] [Google Scholar]
  29. Yosef H., Slater A., Keen C. W., Bunting J. S., Hope-Stone H., Parmar H., Roberts J. T., Termander B., Nilsson B. Prednimustine (Sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer. Eur J Cancer. 1993;29A(8):1100–1105. doi: 10.1016/s0959-8049(05)80296-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES